Address	PMO Hanzomon, 11/F Tokyo Tokyo 102 Japan
Employees	-
Website	http://www.sosei.com
Updated	07/08/2019
Sosei Group Corp. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). Its proprietary StaR (Stabilised Receptor) technology and structure-based drug design (SBDD) platform enables development of drugs for highly validated, yet historically undruggable or challenging GPCRs. The company has multiple programs targeting Alzheimer's disease, schizophrenia, immuno-oncology, migraine, metabolic disease and other rare and specialty indications.